The Medicines and Healthcare products Regulatory Agency has published an interim clinical commissioning policy on remdesivir.
Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency for the use of remdesivir in the treatment of COVID-19, the scientific opinion given for remdesivir via the Early Access to Medicines Scheme put in place on 26 May 2020 has now lapsed.
This interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK. The policy reflects the conditions of the CMA, but also includes secondary criteria to be used should there be limitations in the supply of remdesivir in the UK.
The document, Remdesivir for patients hospitalised with COVID-19 (adults and children of 12 years and older), has also been updated to include updated links to the summary of product characteristics and patient information leaflet for remdesivir.